(Q39200319)

9 September 2017

title

New protein kinase inhibitors in breast cancer: afatinib and neratinib (English)

1 reference

9 September 2017

Xiaosong Zhang

1

1 reference

9 September 2017

Pamela N Munster

series ordinal

2

1 reference

9 September 2017

language of work or name

English

0 references

publication date

30 April 2014

1 reference

Expert Opinion on Pharmacotherapy

9 September 2017

published in

1 reference

9 September 2017

volume

15

1 reference

9 September 2017

issue

9

1 reference

9 September 2017

page(s)

1277-1288

1 reference

Breast cancer statistics, 2013.

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Dual blockade of HER2 - twice as good or twice as toxic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Mechanism of action of trastuzumab and scientific update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Targeted therapies in brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

The development of HKI-272 and related compounds for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Breast cancer metastasis to the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Cardiotoxicity of novel HER2-targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Activating HER2 mutations in HER2 gene amplification negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.913570

10.1517/14656566.2014.913570

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference